Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 1 Interventional Results available

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

ClinicalTrials.gov ID: NCT02616185

Public ClinicalTrials.gov record NCT02616185. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN (VBIR) FOR PROSTATE CANCER (PF-06753512)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with prostate cancer.

Study identification

NCT ID
NCT02616185
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
Pfizer
Industry
Enrollment
91 participants

Conditions and interventions

Interventions

Biological · Device

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 29, 2015
Primary completion
Feb 22, 2021
Completion
Feb 22, 2021
Last update posted
Nov 1, 2023

2015 – 2021

United States locations

U.S. sites
19
U.S. states
10
U.S. cities
13
Facility City State ZIP Site status
Banner-University Medical Center Tucson Tucson Arizona 85719
The University of Arizona Cancer Center-North Campus Tucson Arizona 85719
Smilow Cancer Hospital at Yale-New Haven New Haven Connecticut 06510
Smilow Cancer Hospital Phase 1 Unit New Haven Connecticut 06511
National Institutes of Health Clinical Center Bethesda Maryland 20892
GU Research Network Omaha Nebraska 68130
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89169
Garden State Urology Morristown New Jersey 07960
Morristown Medical Center Morristown New Jersey 07960
Garden State Urology Rockaway New Jersey 07866
Garden State Urology Whippany New Jersey 07981
Northwell Health Lake Success New York 11042
Memorial Sloan-Kettering Cancer Center 53rd Street New York New York 10022
Memorial Sloan Kettering Cancer Center New York New York 10065
Memorial Sloan-Kettering Cancer Center, Sidney Kimmel Center New York New York 10065
Duke University Medical Center Durham North Carolina 27710
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232
Seattle Cancer Care Alliance Seattle Washington 98109
University of Washington Medical Center Seattle Washington 98195

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02616185, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 1, 2023 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02616185 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →